Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D05QGH
|
||||
Former ID |
DIB006127
|
||||
Drug Name |
DXL-625
|
||||
Synonyms |
DXLr-120; Anti-CD20 monoclonal antibodies (DXL, cancer), InNexus; Autophilic peptide conjuagted rituximab (rheumatoid arthritis/NHL/CLL), InNexus; Anti-CD20 monoclonal antibodies (DXL, non-Hodgkin's lymphoma/ rheumatoid arthritis), InNexus
|
||||
Indication | Chronic lymphocytic leukaemia [ICD10:C91] | Investigative | [543668] | ||
Company |
InNexus Biotechnology Inc
|
||||
Target and Pathway | |||||
Target(s) | B-lymphocyte antigen CD20 | Target Info | Modulator | [543668] | |
KEGG Pathway | Hematopoietic cell lineage | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.